epinastine has been researched along with Allergic Conjunctivitis in 23 studies
epinastine: RN given refers parent cpd
epinastine : A benzazepine that is 6,11-dihydro-5H-dibenzo[b,e]azepine in which the azepine ring is fused to the e side of 4,5-dihydro-1H-imidazol-2-amine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Epinastine is effective and safe for the treatment of allergic conjunctivitis." | 9.19 | Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge. ( Fujishima, H; Ohashi, Y; Takamura, E, 2014) |
| "The objective of this study was to compare the efficacy and safety of olopatadine versus epinastine in healthy Japanese adults with a history of allergic conjunctivitis to Japanese cedar pollen." | 9.19 | Efficacy of olopatadine versus epinastine for treating allergic conjunctivitis caused by Japanese cedar pollen: a double-blind randomized controlled trial. ( Ebihara, N; Fukushima, A, 2014) |
| "We aimed to compare the clinical efficacy and ocular surface variables of olopatadine, ketotifen fumarate, epinastine, emedastine and fluorometholone acetate ophthalmic solutions in preventing the signs and symptoms of seasonal allergic conjunctivitis (SAC)." | 9.14 | Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. ( Akman, A; Akova, YA; Borazan, M; Erbek, SS; Karalezli, A; Kiyici, H, 2009) |
| "These healthy adult volunteers with a history of seasonal allergic conjunctivitis had no clinical signs of ocular drying after 4 days of twice-daily treatment with topical epinastine." | 9.12 | An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. ( Ousler, GW; Torkildsen, GL; Workman, DA, 2007) |
| "The aim of this study was to assess the efficacy and tolerability of ophthalmic epinastine in patients with seasonal allergic conjunctivitis (SAC) exposed to environmental allergens." | 9.11 | Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis. ( Abelson, MB; Bradford, R; Lue, J; Schiffman, RM; Whitcup, SM, 2004) |
| "The aim of this study was to assess the efficacy and tolerability of topically administered ophthalmic epinastine using the conjunctival antigen challenge (CAC) model in patients with a history of allergic conjunctivitis." | 9.11 | Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. ( Abelson, MB; Bradford, RR; Crampton, HJ; Gomes, P; Schiffman, RM; Whitcup, SM, 2004) |
| "05% cyclosporine A is as effective as 2% cyclosporine A and epinastine in suppressing mast cell-mediated type I allergic conjunctivitis in an experimental allergic conjunctivitis model." | 7.79 | Comparison of the effects of topical cyclosporine a 0.05%, cyclosporine a 2%, epinastine hydrochloride 0.05%, and prednisolone acetate 1% on allergic inflammation in an experimental allergic conjunctivitis model. ( Nigar, V; Semsettin, B; Sinan, E, 2013) |
| "Epinastine is effective and safe for the treatment of allergic conjunctivitis." | 5.19 | Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge. ( Fujishima, H; Ohashi, Y; Takamura, E, 2014) |
| "The objective of this study was to compare the efficacy and safety of olopatadine versus epinastine in healthy Japanese adults with a history of allergic conjunctivitis to Japanese cedar pollen." | 5.19 | Efficacy of olopatadine versus epinastine for treating allergic conjunctivitis caused by Japanese cedar pollen: a double-blind randomized controlled trial. ( Ebihara, N; Fukushima, A, 2014) |
| "We aimed to compare the clinical efficacy and ocular surface variables of olopatadine, ketotifen fumarate, epinastine, emedastine and fluorometholone acetate ophthalmic solutions in preventing the signs and symptoms of seasonal allergic conjunctivitis (SAC)." | 5.14 | Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. ( Akman, A; Akova, YA; Borazan, M; Erbek, SS; Karalezli, A; Kiyici, H, 2009) |
| "The aim of this study was to compare short-term (5-minute) ocular comfort and drying effects of 3 topical antihistamine/mast cell stabilizers-epinastine, azelastine, and ketotifen-in patients with allergic conjunctivitis (AC)." | 5.13 | Ocular comfort and drying effects of three topical antihistamine/mast cell stabilizers in adults with allergic conjunctivitis: a randomized, double-masked crossover study. ( Gomes, P; Ousler, GW; Torkildsen, GL, 2008) |
| "These healthy adult volunteers with a history of seasonal allergic conjunctivitis had no clinical signs of ocular drying after 4 days of twice-daily treatment with topical epinastine." | 5.12 | An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. ( Ousler, GW; Torkildsen, GL; Workman, DA, 2007) |
| "The aim of this study was to assess the efficacy and tolerability of ophthalmic epinastine in patients with seasonal allergic conjunctivitis (SAC) exposed to environmental allergens." | 5.11 | Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis. ( Abelson, MB; Bradford, R; Lue, J; Schiffman, RM; Whitcup, SM, 2004) |
| "The aim of this study was to assess the efficacy and tolerability of topically administered ophthalmic epinastine using the conjunctival antigen challenge (CAC) model in patients with a history of allergic conjunctivitis." | 5.11 | Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. ( Abelson, MB; Bradford, RR; Crampton, HJ; Gomes, P; Schiffman, RM; Whitcup, SM, 2004) |
| " Ninety-six subjects with a history of allergic conjunctivitis were screened, and the 66 who responded to conjunctival allergen challenge at visits 1 and 2 were randomized into 1 of 3 treatment groups at visit 3 to receive one drop of study medication in each eye: (1) olopatadine in one eye and epinastine in the fellow eye, (2) olopatadine in one eye and placebo in the fellow eye, and (3) epinastine in one eye and placebo in the fellow eye." | 5.11 | Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. ( D'Arienzo, P; Epstein, AB; Finegold, I; Granet, D; Lanier, BQ; Ledgerwood, GL, 2004) |
| "Topical olopatadine is a safe and effective treatment modality for allergic conjunctivitis, whereas alcaftadine appears to be superior to olopatadine in reducing ocular itch." | 4.95 | Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis. ( Chen, LJ; Kam, KW; Wat, N; Young, AL, 2017) |
| "Epinastine is a topical ophthalmic antihistamine and a mast cell stabilizer indicated for treatment of symptoms associated with allergic conjunctivitis." | 4.85 | Epinastine: topical ophthalmic second generation antihistamine without significant systemic side effects. ( Abhishek, K; Mah, F; Pradhan, S, 2009) |
| " In this study, we developed epinastine hydrochloride-releasing daily soft contact lenses for treatment of allergic conjunctivitis and examined their in vitro and in vivo performance." | 3.91 | In vitro and in vivo performance of epinastine hydrochloride-releasing contact lenses. ( Arai, R; Fukushima, A; Hino, S; Ishida, W; Kishimoto, T; Matsunaga, T; Minami, T; Nakajima, I; Yamagami, S, 2019) |
| "05% cyclosporine A is as effective as 2% cyclosporine A and epinastine in suppressing mast cell-mediated type I allergic conjunctivitis in an experimental allergic conjunctivitis model." | 3.79 | Comparison of the effects of topical cyclosporine a 0.05%, cyclosporine a 2%, epinastine hydrochloride 0.05%, and prednisolone acetate 1% on allergic inflammation in an experimental allergic conjunctivitis model. ( Nigar, V; Semsettin, B; Sinan, E, 2013) |
| "Signs of allergic conjunctivitis generally were reduced most by a combination of a CC in combination with ATs or EH." | 2.79 | Effectiveness of nonpharmacologic treatments for acute seasonal allergic conjunctivitis. ( Bilkhu, PS; Kennedy, R; Naroo, SA; Robertson, L; Wolffsohn, JS, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (65.22) | 29.6817 |
| 2010's | 8 (34.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ben-Eli, H | 1 |
| Solomon, A | 1 |
| Minami, T | 1 |
| Ishida, W | 1 |
| Kishimoto, T | 1 |
| Nakajima, I | 1 |
| Hino, S | 1 |
| Arai, R | 1 |
| Matsunaga, T | 1 |
| Fukushima, A | 2 |
| Yamagami, S | 1 |
| Semsettin, B | 1 |
| Sinan, E | 1 |
| Nigar, V | 1 |
| Bilkhu, PS | 1 |
| Wolffsohn, JS | 1 |
| Naroo, SA | 1 |
| Robertson, L | 1 |
| Kennedy, R | 1 |
| Fujishima, H | 1 |
| Ohashi, Y | 1 |
| Takamura, E | 1 |
| Ebihara, N | 1 |
| Kam, KW | 1 |
| Chen, LJ | 1 |
| Wat, N | 1 |
| Young, AL | 1 |
| Tagawa, Y | 1 |
| Namba, K | 1 |
| Nakazono, Y | 1 |
| Iwata, D | 1 |
| Ishida, S | 1 |
| Borazan, M | 1 |
| Karalezli, A | 1 |
| Akova, YA | 1 |
| Akman, A | 1 |
| Kiyici, H | 1 |
| Erbek, SS | 1 |
| Torkildsen, GL | 2 |
| Ousler, GW | 2 |
| Gomes, P | 2 |
| Nichols, KK | 1 |
| Morris, S | 1 |
| Gaddie, IB | 1 |
| Evans, D | 1 |
| Pradhan, S | 1 |
| Abhishek, K | 1 |
| Mah, F | 1 |
| Lambiase, A | 1 |
| Micera, A | 1 |
| Bonini, S | 1 |
| Whitcup, SM | 2 |
| Bradford, R | 1 |
| Lue, J | 1 |
| Schiffman, RM | 2 |
| Abelson, MB | 2 |
| Crampton, HJ | 1 |
| Bradford, RR | 1 |
| Lanier, BQ | 1 |
| Finegold, I | 1 |
| D'Arienzo, P | 1 |
| Granet, D | 1 |
| Epstein, AB | 1 |
| Ledgerwood, GL | 1 |
| Trattler, WB | 1 |
| Luchs, J | 1 |
| Majmudar, P | 1 |
| Friedlaender, MH | 1 |
| Villareal, AL | 1 |
| Farley, W | 1 |
| Pflugfelder, SC | 1 |
| Mah, FS | 1 |
| Rosenwasser, LJ | 1 |
| Townsend, WD | 1 |
| Greiner, JV | 1 |
| Bensch, G | 1 |
| Workman, DA | 1 |
| Galatowicz, G | 1 |
| Ajayi, Y | 1 |
| Stern, ME | 1 |
| Calder, VL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-masked, Comparison Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis - Phase 3, Confirmatory Study -[NCT01363700] | Phase 3 | 87 participants (Actual) | Interventional | Completed | |||
| Randomized Controlled Trial Comparing Olopatadine 0.1% Ophthalmic Solution With Hylo-Dual Ophthalmic Preparation in Children With Seasonal Allergic Conjunctivitis[NCT03186755] | Phase 4 | 42 participants (Anticipated) | Interventional | 2017-06-11 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"A conjunctivitis allergic challenge (CAC) was performed 4 hours after drop instillation. Mean palpebral and bulbar conjunctiva hyperemia was assessed by the investigator at 5, 10, and 20 min post challenge and graded on a 4 points scale of 0-3 (0=none and 3= extremely severe). Total hyperemia score is defined as the sum of the palpebral and bulbar conjunctiva scores.~The endpoint used the average score of three time points (5, 10, and 20 minutes) after allergen challenge ." (NCT01363700)
Timeframe: Visit 7 (5, 10, and 20 minutes post-CAC)
| Intervention | score (Mean) |
|---|---|
| Epinastine (DE-114) Ophthalmic Solution | 2.4 |
| Olopatadine Ophthalmic Solution | 2.7 |
| Placebo Ophthalmic Solution | 3.7 |
"A conjunctivitis allergic challenge (CAC) was performed 4 hours after drop instillation. Mean palpebral and bulbar conjunctiva hyperemia was assessed by the investigator at 5, 10, and 20 min post challenge and graded on a 4 points scale of 0-3 (0=none and 3= extremely severe). Total hyperemia score is defined as the sum of the palpebral and bulbar conjunctiva scores. Count unit was defined each eye.~The endpoint used the average score of three time points (5, 10, and 20 minutes) after allergen challenge ." (NCT01363700)
Timeframe: Visit 5 (5, 10, and 20 minutes post-CAC)
| Intervention | score (Mean) |
|---|---|
| Epinastine (DE-114) Ophthalmic Solution | 2.7 |
| Placebo Ophthalmic Solution | 4.1 |
"A conjunctivitis allergic challenge (CAC) was performed 4 hours after drop instillation. Mean ocular itching score was assessed by the subject at 3, 5, and 10 min post challenge on a 5 points scale of 0-4 where 0=no itching and 4=incapacitating itch.~The endpoint used the average score of three time points (3, 5, and 10 minutes) after allergen challenge ." (NCT01363700)
Timeframe: Visit 7 (3, 5, and 10 minutes post-CAC)
| Intervention | score (Mean) |
|---|---|
| Epinastine (DE-114) Ophthalmic Solution | 0.2 |
| Olopatadine Ophthalmic Solution | 0.2 |
| Placebo Ophthalmic Solution | 1.5 |
"A conjunctivitis allergic challenge (CAC) was performed 4 hours after drop instillation. Mean ocular itching score was assessed by the subject at 3, 5, and 10 min post challenge and graded on a 5 points scale of 0-4 where 0=no itching and 4=incapacitating itch. Count unit was defined each eye.~The endpoint used the average score of three time points (3, 5, and 10 minutes) after allergen challenge ." (NCT01363700)
Timeframe: Visit 5 (3, 5, and 10 minutes post-CAC)
| Intervention | score (Mean) |
|---|---|
| Epinastine (DE-114) Ophthalmic Solution | 0.4 |
| Placebo Ophthalmic Solution | 1.7 |
6 reviews available for epinastine and Allergic Conjunctivitis
| Article | Year |
|---|---|
Topical antihistamines, mast cell stabilizers, and dual-action agents in ocular allergy: current trends.
Topics: Administration, Ophthalmic; Anti-Allergic Agents; Benzazepines; Conjunctivitis, Allergic; Cromolyn S | 2018 |
Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis.
Topics: Administration, Ophthalmic; Anti-Allergic Agents; Benzazepines; Conjunctivitis, Allergic; Dibenzazep | 2017 |
Epinastine: topical ophthalmic second generation antihistamine without significant systemic side effects.
Topics: Clinical Trials as Topic; Conjunctivitis, Allergic; Dibenzazepines; Histamine Antagonists; Humans; I | 2009 |
Multiple action agents and the eye: do they really stabilize mast cells?
Topics: Animals; Anti-Inflammatory Agents; Arachidonic Acid; Conjunctivitis, Allergic; Cytokines; Dibenzazep | 2009 |
Elestat (epinastine HCl ophthalmic solution 0.05%) as a therapeutic for allergic conjunctivitis.
Topics: Animals; Conjunctivitis, Allergic; Dibenzazepines; Dose-Response Relationship, Drug; Histamine H1 An | 2006 |
Epinastine in the management of ocular allergic disease.
Topics: Conjunctivitis, Allergic; Dibenzazepines; Histamine H1 Antagonists; Humans; Imidazoles; Ophthalmic S | 2006 |
12 trials available for epinastine and Allergic Conjunctivitis
| Article | Year |
|---|---|
Effectiveness of nonpharmacologic treatments for acute seasonal allergic conjunctivitis.
Topics: Acute Disease; Adult; Aged; Allergens; Combined Modality Therapy; Conjunctiva; Conjunctivitis, Aller | 2014 |
Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
Topics: Adult; Allergens; Anti-Allergic Agents; Cedrus; Conjunctiva; Conjunctivitis, Allergic; Dibenzazepine | 2014 |
Efficacy of olopatadine versus epinastine for treating allergic conjunctivitis caused by Japanese cedar pollen: a double-blind randomized controlled trial.
Topics: Adult; Allergens; Anti-Allergic Agents; Conjunctivitis, Allergic; Cryptomeria; Dibenzazepines; Doubl | 2014 |
Evaluating the efficacy of epinastine ophthalmic solution using a conjunctivitis allergen challenge model in patients with birch pollen allergic conjunctivitis.
Topics: Adult; Allergens; Anti-Allergic Agents; Betula; Biomarkers; Conjunctivitis, Allergic; Dibenzazepines | 2017 |
Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
Topics: Adolescent; Adult; Anti-Allergic Agents; Benzimidazoles; Child; Conjunctival Diseases; Conjunctiviti | 2009 |
Ocular comfort and drying effects of three topical antihistamine/mast cell stabilizers in adults with allergic conjunctivitis: a randomized, double-masked crossover study.
Topics: Adult; Conjunctivitis, Allergic; Cross-Over Studies; Dibenzazepines; Double-Blind Method; Female; Hi | 2008 |
Epinastine 0.05% ophthalmic solution in contact lens-wearing subjects with a history of allergic conjunctivitis.
Topics: Adolescent; Adult; Aged; Conjunctivitis, Allergic; Contact Lenses; Dibenzazepines; Drug Therapy, Com | 2009 |
Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.
Topics: Adolescent; Adult; Aged; Child; Conjunctivitis, Allergic; Dibenzazepines; Double-Blind Method; Femal | 2004 |
Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis.
Topics: Adolescent; Adult; Aged; Child; Conjunctivitis, Allergic; Dibenzazepines; Double-Blind Method; Femal | 2004 |
Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model.
Topics: Administration, Topical; Adult; Allergens; Anti-Allergic Agents; Conjunctivitis, Allergic; Diagnosti | 2004 |
Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
Topics: Adolescent; Adult; Aged; Allergens; Color; Conjunctivitis, Allergic; Dibenzazepines; Dibenzoxepins; | 2007 |
An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis.
Topics: Administration, Topical; Adolescent; Adult; Conjunctivitis, Allergic; Cross-Over Studies; Dibenzazep | 2007 |
5 other studies available for epinastine and Allergic Conjunctivitis
| Article | Year |
|---|---|
In vitro and in vivo performance of epinastine hydrochloride-releasing contact lenses.
Topics: Animals; Conjunctivitis, Allergic; Contact Lenses, Hydrophilic; Delayed-Action Preparations; Dibenza | 2019 |
Comparison of the effects of topical cyclosporine a 0.05%, cyclosporine a 2%, epinastine hydrochloride 0.05%, and prednisolone acetate 1% on allergic inflammation in an experimental allergic conjunctivitis model.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Conjunctivitis, Allergic; Cyclosporine; | 2013 |
Epinastine ophthalmic solution (Elestat).
Topics: Bites and Stings; Clinical Trials as Topic; Conjunctivitis, Allergic; Dibenzazepines; Eye; Histamine | 2004 |
Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice.
Topics: Administration, Topical; Animals; Conjunctivitis, Allergic; Dibenzazepines; Dibenzoxepins; Female; H | 2006 |
Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.
Topics: Animals; Anti-Allergic Agents; Cell Differentiation; Cell Movement; Cells, Cultured; Conjunctiva; Co | 2007 |